

# Monica Iorfida

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2229203/publications.pdf>

Version: 2024-02-01

15  
papers

364  
citations

1040056

9  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

753  
citing authors

#	ARTICLE	IF	CITATIONS
1	Invasive lobular breast cancer: subtypes and outcome. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 713-723.	2.5	126
2	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 259-265.	2.4	34
3	Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. <i>Cancer Letters</i> , 2017, 400, 276-281.	7.2	34
4	Outcome of Male Breast Cancer: A Matched Single-Institution Series. <i>Clinical Breast Cancer</i> , 2014, 14, 371-377.	2.4	32
5	Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. <i>Breast Care</i> , 2018, 13, 177-181.	1.4	31
6	Outcomes of Patients With Breast Cancer Who Present With Ipsilateral Supraclavicular or Internal Mammary Lymph Node Metastases. <i>Clinical Breast Cancer</i> , 2014, 14, 53-60.	2.4	26
7	Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. <i>British Journal of Cancer</i> , 2019, 121, 325-331.	6.4	25
8	&lt;p&gt;Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives&lt;/p&gt;. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 45-56.	1.8	15
9	Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 328-335.	2.4	13
10	Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review. <i>Future Oncology</i> , 2020, 16, 395-412.	2.4	11
11	Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer. <i>Breast</i> , 2010, 19, 128-132.	2.2	6
12	Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient. <i>Future Oncology</i> , 2015, 11, 23-26.	2.4	6
13	Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. <i>Current Oncology</i> , 2021, 28, 5167-5178.	2.2	3
14	Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. <i>Clinical Breast Cancer</i> , 2015, 15, e257-e262.	2.4	2
15	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1059-1059.	1.6	0